Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rallybio (RLYB) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Rallybio (RLYB) over the last 3 years, with Q3 2025 value amounting to $67.7 million.

  • Rallybio's Liabilities and Shareholders Equity fell 1436.08% to $67.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $244.8 million, marking a year-over-year decrease of 3666.04%. This contributed to the annual value of $68.1 million for FY2024, which is 4109.32% down from last year.
  • Latest data reveals that Rallybio reported Liabilities and Shareholders Equity of $67.7 million as of Q3 2025, which was down 1436.08% from $51.0 million recorded in Q2 2025.
  • In the past 5 years, Rallybio's Liabilities and Shareholders Equity ranged from a high of $162.3 million in Q1 2023 and a low of $51.0 million during Q2 2025
  • Over the past 3 years, Rallybio's median Liabilities and Shareholders Equity value was $92.4 million (recorded in 2024), while the average stood at $97.7 million.
  • Over the last 5 years, Rallybio's Liabilities and Shareholders Equity had its largest YoY gain of 1436.08% in 2025, and its largest YoY loss of 4482.05% in 2025.
  • Over the past 3 years, Rallybio's Liabilities and Shareholders Equity (Quarter) stood at $115.6 million in 2023, then plummeted by 41.09% to $68.1 million in 2024, then fell by 0.66% to $67.7 million in 2025.
  • Its Liabilities and Shareholders Equity was $67.7 million in Q3 2025, compared to $51.0 million in Q2 2025 and $58.0 million in Q1 2025.